PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07K 14/715, 19/00, A61K 38/19

A1

(11) International Publication Number: WO 00/64944

(43) International Publication Date: 2 November 2000 (02.11.00)

(21) International Application Number: PCT/US00/11612

(22) International Filing Date: 28 April 2000 (28.04.00)

(30) Priority Data:
09/301,808 28 April 1999 (28.04.99) US

(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 Cambridge Park Drive, Cambridge, MA 02140 (US).

(72) Inventors: WYNN, Thomas, A.; 1822 Tilton Drive, Silver Spring, MD 20902 (US). CHIARAMONTE, Monica, G.; 12907 Crookston Lane #33, Rockville, MD 20851 (US). COLLINS, Mary; 54 Rathbun Road, Natick, MA 01760 (US). DONALDSON, Debra; 108 Blakely, Medford, MA 02155 (US). FITZ, Lori; 13 Palmer Street, Arlington, MA 02174 (US). NEBEN, Tamlyn; 1115 Danforth Lane, Walnut Creek, CA 94598 (US). WHITTERS, Matthew, J.; 14 Brenton Wood Road, Hudson, MA 01749 (US). WOOD, Clive; 2 Hawthorne Place #17R, Boston, MA 02114 (US).

(74) Agent: GYURE, Barbara, A.; American Home Products Corporation, Patent and Trademark Department-2B, One Campus Drive, Parsippany, NJ 07054 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: TREATMENT OF FIBROSIS BY ANTAGONISM OF IL-13 AND IL-13 RECEPTOR CHAINS

(57) Abstract

Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.